What is the ROCE (Return on Capital Employed) of Haemato this year?
The ROCE of Haemato is 0.06 undefined this year.
Haemato ROCE 2024
Haemato ROCE
0.06
Ticker
HAEK.HM
ISIN
DE000A289VV1
WKN
A289VV
In 2024, Haemato's return on capital employed (ROCE) was 0.06, a -27.18% increase from the 0.08 ROCE in the previous year.
Haemato Aktienanalyse
What does Haemato do?
Haemato AG is a German company specializing in the trade of high-quality pharmaceuticals and medical products. It was founded in 1993 and has become one of the leading companies in this field. The company's goal is to offer quality medications and medical products for the German market. They carefully select products and collaborate with renowned manufacturers and suppliers to ensure success. Haemato AG is divided into different divisions specializing in the trade of various pharmaceuticals and medical products for oncology, pain therapy, rheumatology, and dermatology. They collaborate with Pfizer, Roche, and Merck for oncology medications. For pain therapy, they offer a range of products including pain relievers and specialized therapies. In rheumatology, they focus on diseases of the musculoskeletal system such as osteoporosis and arthritis. They provide a wide range of medications and medical products tailored to these diseases. In dermatology, they specialize in treating skin conditions such as psoriasis and eczema, offering a variety of medications and medical products. They also offer other products including medical devices like injection needles, syringes, EKG machines, and ultrasound devices. Their business model is based on close collaboration with leading manufacturers and suppliers to ensure high-quality products. They also prioritize comprehensive consultation and support for their customers to ensure they receive the right products for their specific needs. In summary, Haemato AG is a leading company in the pharmaceutical and medical product trade, offering a wide range of products and collaborating with top manufacturers and suppliers to provide high-quality and comprehensive solutions for medical needs. Haemato ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROCE Details
Unraveling Haemato's Return on Capital Employed (ROCE)
Haemato's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.
Year-to-Year Comparison
Analyzing Haemato's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.
Impact on Investments
Haemato's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.
Interpreting ROCE Fluctuations
Changes in Haemato’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.
Frequently Asked Questions about Haemato stock
How has the ROCE (Return on Capital Employed) of Haemato developed compared to the previous year?
The ROCE of Haemato has increased by -27.18% decreased compared to the previous year.
What does a high ROCE (Return on Capital Employed) mean for investors of Haemato?
A high Return on Capital Employed (ROCE) indicates that Haemato has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.
What does a low ROCE (Return on Capital Employed) mean for investors of Haemato?
A low ROCE (Return on Capital Employed) can indicate that Haemato has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.
How does an increase in ROCE from Haemato impact the company?
An increase in the ROCE of Haemato can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.
How does a reduction in the ROCE of Haemato affect the company?
A decrease in ROCE of Haemato can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.
What are some factors that can influence the ROCE of Haemato?
Some factors that can affect Haemato's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.
Why is the ROCE of Haemato so important for investors?
The ROCE of Haemato is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.
What strategic measures can Haemato take to improve the ROCE?
To improve the ROCE, Haemato can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.
How much dividend does Haemato pay?
Over the past 12 months, Haemato paid a dividend of 1.1 EUR . This corresponds to a dividend yield of about 7.72 %. For the coming 12 months, Haemato is expected to pay a dividend of 1.12 EUR.
What is the dividend yield of Haemato?
The current dividend yield of Haemato is 7.72 %.
When does Haemato pay dividends?
Haemato pays a quarterly dividend. This is distributed in the months of August, August, August, August.
How secure is the dividend of Haemato?
Haemato paid dividends every year for the past 0 years.
What is the dividend of Haemato?
For the upcoming 12 months, dividends amounting to 1.12 EUR are expected. This corresponds to a dividend yield of 7.83 %.
In which sector is Haemato located?
Haemato is assigned to the 'Health' sector.
Wann musste ich die Aktien von Haemato kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Haemato from 7/21/2023 amounting to 1.2 EUR, you needed to have the stock in your portfolio before the ex-date on 7/19/2023.
When did Haemato pay the last dividend?
The last dividend was paid out on 7/21/2023.
What was the dividend of Haemato in the year 2023?
In the year 2023, Haemato distributed 1.1 EUR as dividends.
In which currency does Haemato pay out the dividend?
The dividends of Haemato are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Haemato
Our stock analysis for Haemato Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Haemato Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.